Subacute oral toxicity and bacterial mutagenicity of a mixture of Puerariae radix and Hizikia fusiforme extracts

Abstract

The study aims to identify the safety profile of a mixed extract (KGC-02-PS) from two traditional medicinal herbs, Puerariae radix and Hizikia fusiforme. In a subacute oral toxicity study, KGC-02-PS was administered orally for 28 days by gavage to Sprague Dawley rats (both sexes) at a daily dose of 0, 500, 1000, and 2000 mg/kg body weight. Bodyweight, food consumption, and clinical signs were monitored during the experimental period. After administering the final dose, this study conducted hematology, serum biochemistry, and pathological evaluations. In addition, the study performed a bacterial reverse mutation test with varying concentrations of KGC-02-PS (312.5 μg − 5,000 μg/plate) following OECD guideline No. 471, before testing five bacterial strains (Salmonella typhimurium TA98, TA100, TA1535, TA1537, and Escherichia coli WP2) in the presence or absence of metabolic activation. The preclinical evaluation of KGC-02-PS’s subacute oral toxicity yielded no associated toxicological effects or any changes in clinical signs, body weight, and food consumption. Moreover, examining KGC-02-PS’s hematological and serum biochemical characteristics and pathology yielded no toxicological changes in terms of organ weight measurements and gross or histopathological findings. KGC-02-PS neither increased the number of revertant colonies in all bacterial strains used in the bacterial reverse mutation test, nor did it induce genotoxicity related to bacterial reverse mutations under the study’s conditions. Also, KGC-02-PS’s no-observed-adverse-effect level was greater than 2000 mg/kg.

Keywords:

• Puerariae radix
• Hizikia fusiforme
• subacute oral toxicity
• bacterial reverse mutagenicity
• no-observed-adverse-effect level

Acknowledgements

The authors are grateful to the Korea Occupational Safety Health Research Institute (Korea) for their technical assistance in conducting the safety tests.

Disclosure statement

The authors report no conflict of interest.

Additional information

Funding

This work was supported by BioNano Health-Guard Research Center funded by the Ministry of Science, ICT & Future Planning (MSIP) of Korea as Global Frontier Project” [Grant No. HGUARD_2013M3A6B2078954] and the Korea Research Institute of Bioscience and Biotechnology (KRIBB) Research Initiative Program (Grant No. KGM2112133).